Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Eltrombopag Use in Chronic Myelomonocytic Leukemia (CMML) Patients: A Cautionary Tale

Hanadi Ramadan, BA, Vu H. Duong, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Ling Zhang, MD, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 2897.

https://doi.org/10.1182/blood.V126.23.2897.2897

Published: 2015

Journal Articles

Myelodysplastic Syndromes in Adolescent Young Adults (AYA)

Joanna (Asia) Grabska, MD, Bijal D. Shah, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Hanadi Ramadan, BA, Jeffrey E Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 2898.

https://doi.org/10.1182/blood.V126.23.2898.2898

Published: 2015

Journal Articles

Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy

Thomas Prebet, MD, Thomas Cluzeau, MDPhD, Sophie Park, MD PhD, Ulrich Germing, MD, Lionel Ades, MD PhD, Uwe Platzbecker, MD, Norbert Vey, Katharina Goetze, MD, Charikleia Kelaidi, MD, Esther Natalie Oliva, Najla H. Al Ali, BDS, MSc, Pierre Fenaux, MD PhD, Steven D. Gore, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 95.

https://doi.org/10.1182/blood.V126.23.95.95

Published: 2015

Journal Articles

Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Rami S. Komrokji, MD, Amy E. DeZern, MD MHS, Katrina Zell, MA, MS, Najla H. Al Ali, BDS, MSc, Christopher Estling, Cassie Zimmerman, MPH, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, PhD, Gail J Roboz, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 909.

https://doi.org/10.1182/blood.V126.23.909.909

Published: 2015

Journal Articles

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Mohamed A. Kharfan-Dabaja, MD, Rami S. Komrokji, MD, Qing Zhang, PhD, David Sallman, MD, Asmita Mishra, MD, Najla H. Al Ali, BDS, MSc, Taiga Nishihori, MD, Teresa Field, MD, PhD, Karma Z Salem, MD, Janelle Perkins, PharmD, Ling Zhang, MD, Lynn C. Moscinski, MD, Hugo F. Fernandez, MD, Jeffrey E Lancet, MD, Alan F. List, MD, Claudio Anasetti, MD, Eric Padron, MD

Blood (2015) 126 (23): 4382.

https://doi.org/10.1182/blood.V126.23.4382.4382

Published: 2015

Journal Articles

P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes

Nguyen Johnny, MD, Kathy L McGraw, PhD, Rami S. Komrokji, MD, David Sallman, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Jeffrey E Lancet, MD, Lynn C. Moscinski, MD, Alan F. List, MD, Ling Zhang, MD

Blood (2015) 126 (23): 4121.

https://doi.org/10.1182/blood.V126.23.4121.4121

Published: 2015

Journal Articles

Prognosis and Outcomes in MDS-MPN Unclassifiable: Single Institution Experience of a Rare Disorder

Ateefa Chaudhury, MD, Rami S. Komrokji, MD, Najla H. Al Ali, BDS, MSc, Ling Zhang, MD, Pardis Vafaii, MD, Jeffrey E. Lancet, MD

Blood (2015) 126 (23): 1698.

https://doi.org/10.1182/blood.V126.23.1698.1698

Published: 2015

Journal Articles

Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)

Rami S. Komrokji, MD, Mintallah Haider, MD, Najla H. Al Ali, BDS, MSc, Jeffrey E Lancet, MD, Qing Zhang, MD, Pearlie K Epling-Burnette, PhD, Alan F. List, MD, Eric Padron, MD

Blood (2015) 126 (23): 1664.

https://doi.org/10.1182/blood.V126.23.1664.1664

Published: 2015

Journal Articles

Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities

David Sallman, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, Mikkael A. Sekeres, MD MS, Amy E. DeZern, MD MHS, David P. Steensma, MD, Gail J. Roboz, MD, John Barnard, PhD, Najla H. Al Ali, BDS, MSc, Cassie Zimmerman, MPH, Sherry Pierce, BSN, BA, Denise Batista, PhD, Jeffrey E Lancet, MD, Eric Padron, MD, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Hagop M. Kantarjian, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 1705.

https://doi.org/10.1182/blood.V126.23.1705.1705

Published: 2015

Journal Articles

Prognostic Impact of ASXL1 Mutations in MDS and CMML

David Sallman, MD, Eric Padron, MD, Christine Vaupel, PhD, Thomas Cluzeau, MDPhD, Najla H. Al Ali, BDS, MSc, Jeffrey E Lancet, MD, Jeff Hall, PhD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 1673.

https://doi.org/10.1182/blood.V126.23.1673.1673

Published: 2015

Journal Articles

Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)

Mikkael A. Sekeres, MD MS, Katrina Zell, MA, MS, John Barnard, PhD, Amy E. DeZern, MD MHS, David P. Steensma, MD, Cassie Zimmerman, MPH, Christopher Estling, MS, Wesley Hand, Gail J. Roboz, MD, Nicole Rizzo, Najla H. Al Ali, BDS, MSc, Alan F. List, MD, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 1696.

https://doi.org/10.1182/blood.V126.23.1696.1696

Published: 2015

Journal Articles

Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)

Rami S. Komrokji, MD, Amy E. DeZern, MD MHS, Katrina Zell, MA, MS, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Christopher Estling, Cassie Zimmerman, MPH, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, PhD, Gail J Roboz, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 1697.

https://doi.org/10.1182/blood.V126.23.1697.1697

Published: 2015

Journal Articles

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Aziz Nazha, MD, Rami S. Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, PhD, Katrina Zell, MA, MS, Cassie Zimmerman, MPH, Najla H. Al Ali, BDS, MSc, Gail J Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Eric Padron, MD, Elias J. Jabbour, MD, Molly Dara Greenberg, BS, Alan F. List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 2888.

https://doi.org/10.1182/blood.V126.23.2888.2888

Published: 2015

Journal Articles

Myelodysplastic Syndrome: A Study of VA Population.

Gina M. Matacia-Murphy, MD, Najla H. Al Ali, BDS, Jeffrey A. Schrager, MD, M.S. Beg, MD, Malek M. Safa, MD, Rami S. Komrokji, MD

Blood (2007) 110 (11): 2470.

https://doi.org/10.1182/blood.V110.11.2470.2470

Published: 2007

Journal Articles

Outcome of Diffuse Large B Cell Lymphoma in the United States: Review of SEER Data.

Rami S. Komrokji, MD, Najla H. Al Ali, BDS, S.M. Beg, MD, Jeffrey A. Schrager, MD, Malek M. Safa, MD

Blood (2007) 110 (11): 1567.

https://doi.org/10.1182/blood.V110.11.1567.1567

Published: 2007

NARROW

Eltrombopag Use in Chronic Myelomonocytic Leukemia (CMML) Patients: A Cautionary Tale

Myelodysplastic Syndromes in Adolescent Young Adults (AYA)

Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy

Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes

Prognosis and Outcomes in MDS-MPN Unclassifiable: Single Institution Experience of a Rare Disorder

Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS)

Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities

Prognostic Impact of ASXL1 Mutations in MDS and CMML

Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)

Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Myelodysplastic Syndrome: A Study of VA Population.

Outcome of Diffuse Large B Cell Lymphoma in the United States: Review of SEER Data.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only